AU2017204685B2 - Compositions and methods for detecting and treating gastric cancer - Google Patents

Compositions and methods for detecting and treating gastric cancer Download PDF

Info

Publication number
AU2017204685B2
AU2017204685B2 AU2017204685A AU2017204685A AU2017204685B2 AU 2017204685 B2 AU2017204685 B2 AU 2017204685B2 AU 2017204685 A AU2017204685 A AU 2017204685A AU 2017204685 A AU2017204685 A AU 2017204685A AU 2017204685 B2 AU2017204685 B2 AU 2017204685B2
Authority
AU
Australia
Prior art keywords
cdr
progastrin
antibodies
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017204685A
Other languages
English (en)
Other versions
AU2017204685A1 (en
Inventor
Alexandre PRIEUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progastrine et Cancers SARL
Original Assignee
Progastrine et Cancers SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine et Cancers SARL filed Critical Progastrine et Cancers SARL
Publication of AU2017204685A1 publication Critical patent/AU2017204685A1/en
Application granted granted Critical
Publication of AU2017204685B2 publication Critical patent/AU2017204685B2/en
Priority to AU2022263503A priority Critical patent/AU2022263503B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/5753—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2017204685A 2015-12-31 2017-01-02 Compositions and methods for detecting and treating gastric cancer Active AU2017204685B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022263503A AU2022263503B2 (en) 2015-12-31 2022-11-02 Compositions and methods for detecting and treating gastric cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15307191 2015-12-31
EP15307191.5 2015-12-31
EP16305131.1 2016-02-05
EP16305131 2016-02-05
PCT/EP2017/050036 WO2017114975A1 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating gastric cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022263503A Division AU2022263503B2 (en) 2015-12-31 2022-11-02 Compositions and methods for detecting and treating gastric cancer

Publications (2)

Publication Number Publication Date
AU2017204685A1 AU2017204685A1 (en) 2018-07-12
AU2017204685B2 true AU2017204685B2 (en) 2022-10-13

Family

ID=57821945

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017204685A Active AU2017204685B2 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating gastric cancer
AU2022263503A Active AU2022263503B2 (en) 2015-12-31 2022-11-02 Compositions and methods for detecting and treating gastric cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022263503A Active AU2022263503B2 (en) 2015-12-31 2022-11-02 Compositions and methods for detecting and treating gastric cancer

Country Status (12)

Country Link
US (2) US12474343B2 (enExample)
EP (2) EP3397966B1 (enExample)
JP (3) JP6909795B2 (enExample)
KR (2) KR102477179B1 (enExample)
CN (1) CN108700588A (enExample)
AU (2) AU2017204685B2 (enExample)
BR (1) BR112018013268A2 (enExample)
CA (2) CA3009740A1 (enExample)
EA (1) EA037027B1 (enExample)
ES (2) ES3011729T3 (enExample)
SG (1) SG11201805141QA (enExample)
WO (1) WO2017114975A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3720879B1 (en) * 2017-12-05 2022-05-11 Progastrine et Cancers S.à r.l. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
AU2018381046B2 (en) 2017-12-08 2025-10-02 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
WO2019166499A1 (en) 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
KR102379022B1 (ko) 2019-05-24 2022-03-28 주식회사 엠디헬스케어 qPCR 분석을 통한 위암 진단방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083091A2 (en) * 2010-01-08 2011-07-14 Bioréalités S.A.S. Methods for treating pancreatic cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
FI20011908A7 (fi) * 2001-09-28 2003-03-29 Biohit Oyj Menetelmä vatsasyövän osoittamiseksi
JP2008513536A (ja) * 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
US7854932B2 (en) * 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP2488551B1 (en) 2009-10-16 2018-07-25 Progastrine et Cancers S.à r.l. Monoclonal antibodies to progastrin and their uses
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
CN101797382B (zh) * 2010-03-03 2013-11-20 戚胜美 抗人前胃液素多肽免疫组合物
US8674064B2 (en) * 2010-03-03 2014-03-18 Onkologix Ltd Immunogenic compositions against human progastrin peptides
SG184092A1 (en) * 2010-03-24 2012-10-30 Biorealites Prophylaxis of colorectal and gastrointestinal cancer
ES2871092T3 (es) 2010-07-26 2021-10-28 Progastrine Et Cancers S A R L Métodos y composiciones para la terapia del cáncer de hígado

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083091A2 (en) * 2010-01-08 2011-07-14 Bioréalités S.A.S. Methods for treating pancreatic cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QING HE ET AL.: "Anti-Gastrins Antiserum Combined with Lowered Dosage Cytotoxic Drugs to Inhibit the Growth of Human Gastric Cancer SGC7901 Cells in Nude Mice", 《JOURNAL OF CANCER》 *

Also Published As

Publication number Publication date
EA201891528A1 (ru) 2019-01-31
CN108700588A (zh) 2018-10-23
AU2017204685A1 (en) 2018-07-12
KR102428255B1 (ko) 2022-08-03
US20240402181A1 (en) 2024-12-05
CA3193501A1 (en) 2017-07-06
EP3397966B1 (en) 2021-09-29
KR20220100099A (ko) 2022-07-14
ES2899360T3 (es) 2022-03-11
JP2024041982A (ja) 2024-03-27
AU2022263503B2 (en) 2025-01-23
JP2019505784A (ja) 2019-02-28
KR102477179B1 (ko) 2022-12-13
ES3011729T3 (en) 2025-04-08
JP2021167831A (ja) 2021-10-21
JP7478708B2 (ja) 2024-05-07
CA3009740A1 (en) 2017-07-06
US20190011449A1 (en) 2019-01-10
EA037027B1 (ru) 2021-01-27
EP3954998A1 (en) 2022-02-16
JP6909795B2 (ja) 2021-07-28
WO2017114975A1 (en) 2017-07-06
BR112018013268A2 (pt) 2018-12-11
EP3954998B1 (en) 2024-12-25
EP3954998C0 (en) 2024-12-25
US12474343B2 (en) 2025-11-18
SG11201805141QA (en) 2018-07-30
EP3397966A1 (en) 2018-11-07
AU2022263503A1 (en) 2022-12-08
KR20180105642A (ko) 2018-09-28

Similar Documents

Publication Publication Date Title
US20240085423A1 (en) Compositions and methods for detecting and treating esophageal cancer
AU2021250840B2 (en) Compositions and methods for detecting and treating ovarian cancer
US20240402181A1 (en) Compositions and methods for detecting and treating gastric cancer
US20240018264A1 (en) Compositions and methods for detecting and treating ovarian cancer
HK1262046A1 (en) Compositions and methods for detecting and treating esophageal cancer
HK1262046B (en) Compositions and methods for detecting and treating esophageal cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)